Fennec Pharmaceuticals

FENC

Market cap $234M

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company's common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.

Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to a loss of $0.06 per share a year ago.

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ®  Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin Chemotherapy Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin Chemotherapy

Adherex Technologies (FENC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.